Paper41003906
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.
Jamialahmadi T and 6 others. Curr Atheroscler Rep, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis. Papers, record 41003906. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41003906
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pioglitazone | Major topic |
| Lipoprotein(a) | Major topic |
| Hypoglycemic Agents | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Humans |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19835463 | Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. | Curr Med Res Opin | 2009 | https://conductscience.org/library/papers/19835463 | PubMed |
| 2 | 40231787 | Experimental Models to Investigate PNPLA3 in Liver Steatosis. | Liver Int | 2025 | https://conductscience.org/library/papers/40231787 | PubMed |
| 3 | 20965889 | Lipoprotein(a) as a cardiovascular risk factor: current status. | Eur Heart J | 2010 | https://conductscience.org/library/papers/20965889 | PubMed |
| 4 | 26171320 | Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications. | Sci Pharm | 2014 | https://conductscience.org/library/papers/26171320 | PubMed |
| 5 | 22998429 | Lipoprotein(a): resurrected by genetics. | J Intern Med | 2013 | https://conductscience.org/library/papers/22998429 | PubMed |
| 6 | 36036785 | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. | Eur Heart J | 2022 | https://conductscience.org/library/papers/36036785 | PubMed |
| 7 | 22686416 | Basal insulin and cardiovascular and other outcomes in dysglycemia. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22686416 | PubMed |
| 8 | 17275945 | Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. | Diabetes Res Clin Pract | 2007 | https://conductscience.org/library/papers/17275945 | PubMed |
| 9 | 24710641 | Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. | Exp Clin Endocrinol Diabetes | 2014 | https://conductscience.org/library/papers/24710641 | PubMed |
| 10 | 28057658 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. | BMJ Open | 2017 | https://conductscience.org/library/papers/28057658 | PubMed |
| 11 | 32466884 | Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them. | J Am Coll Cardiol | 2020 | https://conductscience.org/library/papers/32466884 | PubMed |
| 12 | 40066493 | Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease. | Eur J Prev Cardiol | 2025 | https://conductscience.org/library/papers/40066493 | PubMed |
| 13 | 18690882 | Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. | Curr Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18690882 | PubMed |
| 14 | 37442270 | Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? | Metabolism | 2023 | https://conductscience.org/library/papers/37442270 | PubMed |
| 15 | 39270008 | Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 Cells. | J Cardiovasc Pharmacol | 2024 | https://conductscience.org/library/papers/39270008 | PubMed |
| 16 | 21207250 | Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. | Lipids | 2011 | https://conductscience.org/library/papers/21207250 | PubMed |
| 17 | 38418000 | Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. | J Am Coll Cardiol | 2024 | https://conductscience.org/library/papers/38418000 | PubMed |
| 18 | 16861090 | Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. | Clin Ther | 2006 | https://conductscience.org/library/papers/16861090 | PubMed |
| 19 | 20977573 | Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us? | Diabetes Obes Metab | 2010 | https://conductscience.org/library/papers/20977573 | PubMed |
| 20 | 25713100 | IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. | J Lipid Res | 2015 | https://conductscience.org/library/papers/25713100 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985587 | Lipoprotein(a) and Prognostic Nutritional Index Levels Exhibit Interactive and Joint Effects on Mortality Risk in Patients With Coronary Artery Disease: Findings From a Real-World Study. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42985587 | PubMed |
| 42111957 | The Impact of Current and Emerging Therapies on Lipoprotein(a). | Eur Cardiol | 2026 | https://conductscience.org/library/papers/42111957 | PubMed |
| 41923065 | Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control. | Lipids Health Dis | 2026 | https://conductscience.org/library/papers/41923065 | PubMed |
| 41680637 | Positive association of lipoprotein(a) and the prevalence of lower extremity arterial disease in MASLD: a cross-sectional study. | BMC Cardiovasc Disord | 2026 | https://conductscience.org/library/papers/41680637 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| LPA | 4018 | PubTator's text mining | https://conductscience.org/library/genes/4018 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41003906
GET https://conductscience.org/api/papers/v1/41003906/references?page=2